Adil Daud

MD

Oncologist and melanoma specialist
Immunotherapy researcher, history and literature buff

About me

Dr. Adil Daud, an oncologist, specializes in melanoma and other skin cancers. He is co-director of the Melanoma Center. In addition to caring for patients, he directs research to better understand the biology of melanoma and to develop new treatments. He has developed and led many clinical trials that have expanded the use of gene therapy for melanoma.

Daud earned a medical degree at the Government Medical College, Nagpur. He completed both an internship and a residency in internal medicine at Indiana University School of Medicine, followed by a fellowship in hematology-oncology at Memorial Sloan Kettering Cancer Center. Prior to joining UCSF Medical Center, he was a researcher at the Moffitt Cancer Center in Tampa, Florida, for seven years.

Daud has won numerous awards, including a Young Investigator Award from the American Society of Clinical Oncology and selection as a Castle Connolly Top Doctor.

  • Education

    Government Medical College, Nagpur, 1986

  • Residencies

    Indiana University School of Medicine, 1997

  • Fellowships

    Memorial Sloan-Kettering Cancer Center, 2000

  • Board Certifications

    Internal Medicine, American Board of Internal Medicine

    Medical Oncology, American Board of Internal Medicine

  • Academic Title

    Professor

  • Languages

    Hindi

The future of cancer therapy is here, and it is immunotherapy. And it arrived a lot sooner than expected!

Melanoma & Skin Cancer Program

Bakar Precision Cancer Medicine Building

1825 Fourth Street, Third Floor
San Francisco, CA 94158

Selected research

Decorative Caduceus

Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma

Point estimates of ORR and 95% confidence intervals will be provided.

Recruiting

Decorative Caduceus

A Study to Evaluate The Efficacy And Safety Of RO7198457 In Combination With Pembrolizumab Vers...

Recruiting

Decorative Caduceus

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Recruiting

Decorative Caduceus

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

Treatment-related adverse events as assessed by CTCAE v4.03

Recruiting

Share